Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70625 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Petrice M Cogswell und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Biomarkers, Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, Alzheimer's Association, Swedish Research Council.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Plasma biomarkers’ utility for predicting incident mild cognitive impairment (MCI) remains unclear. We evaluated associations of plasma Alzheimer's disease (AD) biomarkers and amyloid positron emission tomography (PET) with transitions from cognitively unimpaired (CU) to MCI in the Mayo Clinic Study of Aging (MCSA) and BioFINDER‐2 studies. METHODS Associations of continuous baseline plasma biomarker levels and amyloid PET Centiloid with progression to MCI, adjusting for age, sex, and education, were evaluated with Cox proportional hazards models. RESULTS The study included 381 MCSA and 584 BioFINDER‐2 participants. Amyloid PET and percent phosphorylated to non‐phosphorylated tau217 (%p‐tau217) were strong predictors of progression to MCI in both cohorts: hazard ratios of 1.49 and 1.23 in the MCSA and 1.72 and 1.65 in BioFINDER, respectively. Amyloid beta 42/40 was a significant predictor in BioFINDER‐2 only (hazard ratio 2.20). DISCUSSION Plasma %p‐tau217 was associated with progression from CU to MCI in both cohorts, although differences in biomarker associations may be related to differences in the two cohorts. Highlights Mass‐spectrometry‐based plasma phosphorylated tau217 was associated with cognitively unimpaired to mild cognitive impairment (MCI) progression. Plasma amyloid beta 42/40 was a significant predictor in BioFINDER but not the Mayo Clinic Study of Aging (MCSA). Amyloid positron emission tomography (PET) was the strongest predictor of progression to MCI in the MCSA. Plasma had added value to amyloid PET in BioFINDER but not the MCSA. Biomarker performance may vary with cohort and biomarker measurement differences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Data Science, University of Mississippi Medical Center, Jackson, Mississippi, USA.
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
- Memory Clinic, Skåne University Hospital, Malmö, Sweden.
- Department of Neurology, Washington University, St. Louis, Missouri, USA.
Förderung
- NIH HHS
- Alzheimer's Association
- Swedish Research Council
- Swedish Brain Foundation
- NIA NIH HHS
- Swedish federal government under the ALF agreement
- Cure Alzheimer's Fund
- ERA PerMed
Zitieren
APA
Cogswell, P. M., Wiste, H. J., Therneau, T. M., Griswold, M. E., Mattsson-Carlgren, N., Palmqvist, S., Binette, A. P., Stomrud, E., Bateman, R. J., Barthelemy, N., Braunstein, J. B., West, T., Verghese, P. B., Machulda, M. M., Graff-Radford, J., Algeciras-Schimnich, A., Lowe, V. J., Schwarz, C. G., Senjem, M. L., …, & Jack, C. R. (2025). Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70625
Vancouver
Cogswell PM, Wiste HJ, Therneau TM, Griswold ME, Mattsson-Carlgren N, Palmqvist S, et al. Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70625
BibTeX
@article{Cogswell2025,
author = {Cogswell, Petrice M and Wiste, Heather J and Therneau, Terry M and Griswold, Michael E and Mattsson-Carlgren, Niklas and Palmqvist, Sebastian and Binette, Alexa Pichet and Stomrud, Erik and Bateman, Randall J and Barthelemy, Nicolas and Braunstein, Joel B and West, Tim and Verghese, Philip B and Machulda, Mary M and Graff-Radford, Jonathan and Algeciras-Schimnich, Alicia and Lowe, Val J and Schwarz, Christopher G and Senjem, Matthew L and Gunter, Jeffrey L and Knopman, David S and Vemuri, Prashanthi and Petersen, Ronald C and Hansson, Oskar and Jack, Clifford R},
title = {Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70625}
}
EUVIMED